Zempia

Zempia (E-101 Solution) is a first-in-class, topical biological antimicrobial developed by Exoxemis. It utilizes a porcine myeloperoxidase (pMPO) enzyme system to generate highly reactive singlet oxygen and hypochlorous acid. This enzymatic process mimics the natural immune response of neutrophils to kill a broad spectrum of pathogens, including antibiotic-resistant bacteria, viruses, fungi, and spores. The formulation consists of pMPO, glucose oxidase (GO), glucose, and sodium chloride in an aqueous solution. It has been evaluated in Phase 3 clinical trials for the prevention of surgical site infections and has shown potential in treating urinary tract infections, ventilator-associated pneumonia, and biodefense applications such as anthrax. The drug is designed for topical application to open wounds and has demonstrated safety without interfering with normal wound healing.

Brand names

Zempia

Other names

porcine myeloperoxidasepMPO